wolfschanzze
BANNED
- Joined
- Jul 6, 2013
- Messages
- 4,838
- Reaction score
- -25
- Country
- Location
only 30? have you seen ours?ranbaxy ,cipla etc. those are enough
Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature may not be available in some browsers.
only 30? have you seen ours?ranbaxy ,cipla etc. those are enough
see, lvl of your brain ? ahahhaha go check that link againonly 30? have you seen ours?ranbaxy ,cipla etc. those are enough
lol dont need to,we retain the biggest generic drug market share in world and it wouldnt hurt us to sell unlabelled drugs to bangladeshi pharma companies who repack them with their pharma company seal made in bangladesh.see, lvl of your brain ? ahahhaha go check that link again
no wonder you are a chutiyalol dont need to,we retain the biggest generic drug market share in world and it wouldnt hurt us to sell unlabelled drugs to bangladeshi pharma companies who repack them with their pharma company seal made in bangladesh.
Either way we are getting money from bangladesh
Bangladesh holds huge potential for Indian pharmano wonder you are a chutiya
now you turned to be big chutiya buying huge amount of raw materials from India and depending on India are different thingBangladesh holds huge potential for Indian pharma
A Raju, Hyderabad
Thursday, September 20, 2012, 08:00 Hrs [IST]
Though at a nascent stage, Bangladesh holds huge potential for the Indian pharma companies to tap. Since much potential exists for developing trade and economic relations between the two countries, both the nations should move ahead to tap the emerging opportunities, aver experts.
While on the one hand , India being a well established country in pharma segment can assist Bangladesh to grow, on the other Indian companies can gain from exports, they point out.
Having India in its neighbourhood with a strong base in the pharma sector, Bangladesh is a big importer of pharma and infrastructure raw materials from India for its domestic consumption and commercial purposes.
Bangladesh is importing huge quantities of APIs from India for its domestic pharma industry needs. As the country is aiming to develop its own API manufacturing base, it could well utilize the services of India and can enter into joint ventures with Indian companies for technology transfer and sharing other aspects of the industry.
Over the years, India and Bangladesh have taken a number of initiatives to remove “invisible” trade barriers such as elimination of tariffs and non-tariff restrictions at the unilateral, bilateral, and regional levels. India has become Bangladesh’s largest trading partner in South Asia.
Having recognized the huge potential of the budding pharmaceutical sector in Bangladesh, India with its well established and globally renowned pharmaceutical base can play a vital role in terms of technology transfer, providing training, imparting knowledge on various related subjects of pharma and biotechnology and thereby can develop mutual trade relations and become one of Asia’s dominant players.
Bangladesh holds huge potential for Indian pharma
Read this now who is the lungi chutiya
read it well Bangladesh depends on India for everything, be it pharma products or infrastructure. sabse bada chutiyanow you turned to be big chutiya buying huge amount of raw materials from India and depending on India are different thing
only 30? have you seen ours?ranbaxy ,cipla etc. those are enough
It is a routine of West pharma companies to pull up Indian pharma companies over many things sometimes unspecified to vent their frustration and anger over india stealing their Drug market in India which is huge 1.2 billion people worth of market and all developing countries.Naturally we expect many lawsuits against our companies as they will try to oppose us,defame,ban indian companies in countries which they consider as their market.Generic Lipitor lots recalled due to glass particles; Ranbaxy yanks 40 lots of the cholesterol drug
Ranbaxy, a subsidiary of Ranbaxy Laboratories Ltd., India's biggest drugmaker, is operating under increased scrutiny from the U.S. Food and Drug Administration because of quality lapses at multiple Ranbaxy factories over the past several years.
Read more: Generic Lipitor lots recalled due to glass particles; Ranbaxy yanks 40 lots of the cholesterol drug - NY Daily News